What is the appropriate prednisolone dosage and duration for severe acute alcoholic hepatitis without contraindications such as active infection, uncontrolled diabetes, or gastrointestinal bleeding?

Prednisolone Dosage in Acute Alcoholic Hepatitis

For severe acute alcoholic hepatitis without contraindications, administer prednisolone 40 mg daily for 28 days, with treatment response assessed at day 7 using the Lille score to determine whether to continue or stop therapy. 1, 2

Eligibility Criteria

Before initiating corticosteroids, confirm the following:

• Maddrey Discriminant Function (MDF) ≥32 or MELD score >20 1, 2
• Exclude active infection through systematic screening (chest x-ray, blood, urine, and ascites cultures) 1
• Rule out uncontrolled gastrointestinal bleeding 1
• Ensure serum creatinine <2.5 mg/dL 1
• Exclude concomitant conditions: HBV, HCV, drug-induced liver injury, hepatocellular carcinoma, acute pancreatitis, HIV, tuberculosis 1
• Confirm no multiorgan failure or shock 1

Important caveat: Recent evidence suggests taking up to one week from admission to systematically evaluate patients before initiating steroids, as this allows proper infection screening and stabilization 3. The median time from admission to steroid initiation in clinical trials was 6.5 days 3.

Dosing Regimen

Standard protocol:

• Prednisolone 40 mg daily (or methylprednisolone 32 mg daily equivalent) 1, 2
• Duration: 28 days total if treatment response is adequate 1, 2
• Can be stopped abruptly or tapered over 3 weeks after completing the 28-day course 2

Emerging evidence on tapering: A 2025 randomized trial demonstrated that a rapid taper regimen (40 mg/day tapered by 10 mg/week over 4 weeks) significantly reduced infection rates compared to fixed dosing (19.7% vs 33.1%, HR 0.57, p=0.03) without compromising mortality, AKI incidence, or other outcomes 4. This suggests the lowest possible steroid exposure with a two-week taper may be preferable 3.

Response Assessment and Treatment Modification

At Day 7, calculate the Lille score:

• Lille score <0.45: Continue prednisolone for full 28 days 1, 2
• Lille score ≥0.45: Stop corticosteroids immediately, particularly in null responders (Lille ≥0.56) 1, 2

This stopping rule is critical because non-responders derive no benefit from continued steroid exposure and face unnecessary infection risk. After stopping steroids in non-responders, consider early liver transplantation evaluation in highly selected patients 2.

Monitoring and Complications

Vigilant surveillance is essential during the first month:

• Most infections occur within the first 30 days of treatment 3
• Common adverse events include infections (most frequent), gastrointestinal bleeding, and renal impairment 3
• Infection prevalence ranges from 12-26% at admission, with up to 50% developing infection during corticosteroid therapy 1
• Post-treatment mortality risk persists, with some studies showing higher mortality in the immediate weeks after completing steroids, primarily due to infections 5

Concurrent Management

Nutritional support is mandatory:

• Target 35-40 kcal/kg body weight daily 2
• Protein intake: 1.2-1.5 g/kg/day 2
• Prefer oral route as first-line; enteral feeding if necessary 2
• Patients with calorie intake <21.5 kcal/kg have significantly higher mortality and infection risk 2
• Supplement with B-complex vitamins 2

Consider adding N-acetylcysteine (though evidence is mixed) 1

Key Clinical Pitfalls

1. Don't rush steroid initiation - Use the first week to thoroughly screen for infection and assess spontaneous improvement 3
2. Don't continue steroids in non-responders - The Lille score at day 7 is your decision point; continuing beyond this in non-responders only increases harm 1, 2
3. Don't neglect nutrition - Inadequate caloric intake independently predicts mortality regardless of steroid therapy 2
4. Don't assume all contraindications are absolute - Emerging data suggests some previously absolute contraindications (controlled infection, stabilized GI bleeding) may be relative once the condition is managed 6

Special Populations

Patients with early spontaneous improvement: Recent 2026 data suggests that patients with >10% spontaneous bilirubin decline within 5-10 days of admission may not benefit from corticosteroids (90-day survival 79% vs 83%, p=0.76), though this trial was underpowered 7. This supports a brief observation period to identify patients who may be spared steroid therapy.